Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)

There is no fulltext present in this item.

Title:	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
Author(s):	Maschmeyer, G.; Greef, J. van der; Mellinghoff, S.C.; Nosari, A.; Thiebaut-Bertrand, A.; Bergeron, A.; Franquet, T.; Blijlevens, N.M. ; Maertens, J.A.
Publication year:	2019
Source:	Leukemia, vol. 33, iss. 4, (2019), pp. 844-862
ISSN:	0887-6924
Related links:	https://www.nature.com/articles/s41375%2D019%2D0388%2Dx.pdf
DOI:	https://doi.org/10.1038/s41375-019-0388-x
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/202812
Display more details
Subject:	Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences
Organization:	Haematology
Journal title:	Leukemia
Volume:	vol. 33
Issue:	iss. 4
Page start:	p. 844
Page end:	p. 862
Abstract:	A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed.